. Initial approaches to gene editing were largely confined to simple rearrangements of DNA through the use of restriction enzymes and ligases in vitro or in bacteria. These techniques are inherently limited by the intrinsic sequence-specific nature of restriction enzymes and, consequently, by the functional inability to edit higher-order organisms. Indeed, the primary options for manipulating eukaryotic genomes were inducing random mutations using chemicals and radiation, nontargeted DNA integration using speciescompatible transposon elements and viruses or directed breeding and/or evolution through matching of parents with desired alleles. Despite their limitations, these approaches have enabled many advances, including the generation of gene knockouts and knock-ins via transgenic expression and homologous recombination (HR) in embryonic stem cells, and have led to initial attempts at gene therapy by exogenous gene expression.
The development of custom programmable DNA nucleases began with the creation of the ZFN 1,2 , was advanced in precision and usability by the development of the TALEN 3, 4 and was made highly accessible through the development of CRISPR-based systems 3, 4 (FiG. 1) . The shared ability of these gene editors to target unique DNA locations in the genome is an essential core function for genome editing systems.
The addition of various enzymatic activities, such as double-stranded nucleases, base editors or DNA methyltransferases, to these programmable DNAbinding platforms has increased the versatility of precision gene editing. Upon interacting with their defined loci, these platforms activate endogenous DNA repair mechanisms that serve as the molecular pathways to generate a wide range of DNA sequence edits. Current genomic editing approaches use at least five different DNA repair pathways to induce DNA sequence changes: non-homologous end joining (NHEJ), which is induced by a targeted double-strand break (DSB) from an associated nuclease; classical HR; single-strand template repair (SSTR); microhomology-mediated end joining (MMEJ); and endogenous base mismatch repair, which edits DNA without creating a DSB. Each of these mechanisms differs in terms of the cellular
Programmable DNA nucleases
A DNA-binding platform that can be customized to bind to a specific DNA sequence and introduce a DSB in this targeted manner.
Transposon elements
DNA sequences that can be translocated within the genome by transposase proteins.
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processes, the resulting mutation signatures and the potential uses in genomic science.
Successful genome engineering also depends on the cellular context, with editing efficacy being modulated by stage in the cell cycle, cell type and other conditions within the cellular environment. In basic science research, DNA editing can be used to study gene function and to create engineered lines of experimental animals. This tool also enables the generation of accurate disease models in a number of cellular systems and animals and has enormous potential for clinical applications. In particular, multiple genetic events and their interactions can be mimicked to aid the understanding of complex genetic disorders, including common renal diseases.
In this Review, we focus on the development, mechanisms and accessibility of the various DNA editing platforms as well as their targeted interactions with the genome. We also discuss current understanding of the biochemical functions that are used to make DNA modifications for modern precision gene editing and highlight the applications and potential of this technology in the field of nephrology.
Programmable DNA-targeting platforms

Zinc fingers
The first custom programmable DNA-binding platform was developed from the ~30-amino-acid Cys2-His2 zinc-finger (ZF) domain, which is the most abundant DNA-binding protein motif utilized in eukaryotic transcription factors 1, [8] [9] [10] (FiG. 1a) . In each ZF domain, three amino-acid clusters (known as fingers) each recognize a single specific DNA base and mediate DNA binding [10] [11] [12] . In principle, manipulation of the amino acids in each finger can be used to create a ZF that can bind to any one of the 64 possible three-base permutations 13 . Multiple ZF domains can be fused together to create a single polyprotein that is capable of binding long stretches of DNA [14] [15] [16] . ZFs have restricted accessibility owing to limitations relating to their synthesis and targeting flexibility.
For example, the generation of custom ZFs can be technically arduous, as synthesized tandem ZF repeats often exhibit unpredictable context-specific interference that abrogates binding and reduces or alters specificity 10 . Historically, these technical limitations meant that only a subset of the genome was targetable using this system 17 . However, progress in protein design and compatibility has improved the ZFN platform 18 . As ZFs have no intrinsic editing ability, creating an editor from the ZF DNA-binding domain required the attachment of a DNA endonuclease. Such an editorthe ZFN -was created by fusing the FokI endonuclease domain to the carboxy-terminal end of a series of tandem ZF domains 1, 19 . The binding of two ZFNs to DNA enables FokI to dimerize, become catalytically active and induce a DSB between the ZF binding domains 9 . The DSB repair pathway can then be utilized for precision gene editing [20] [21] [22] . The specificity of the ZF binding platform is increased by the requirement for two ZFNs to bind in close proximity in order to bring the FokI subunits together and enable DNA cutting activity 19 . Modification of the FokI dimerization interface to create an obligate heterodimer system further increased the specificity of the ZFN system [23] [24] [25] . Although the creation of ZFNs was a critical advance in gene editing technology, their use has been modest owing to the engineering challenges associated with context-dependent assembly constraints [26] [27] [28] . However, the long-term impact of ZFNs on the field of gene editing cannot be overstated. Nearly all of the genomic science approaches that are commonly used today, such as the creation of artificial transcription factors, were originally tested using this first-generation programmable DNA editing platform, and ZFNs are the first custom nuclease system to be deployed in clinical trials. Often working in relative obscurity, ZF researchers were the innovators who developed the core technology that is used today for modern gene editing.
Transcription activator-like effectors
After nearly two decades of pioneering work using ZFNs, a second-generation programmable DNA-binding platform was developed from DNA-binding factors identified in the plant bacterial pathogen Xanthomonas 29,30 (FiG. 1b) . Transcription activator-like effector (TALE) domains consist of a series of modular 33-35 aminoacid repeats, each of which binds a single specific DNA base 29, 31 . Two hypervariable residues central to the repeat determine the binding specificity of each repeat 29, 32 . These repeat variable di-residues (RVDs) are flanked on either side by constant amino-acid sequences. The modular amino-acid repeats can be joined together to form a long polypeptide capable of binding stretches of DNA in excess of 20 bases 33 . On the basis of prior work using ZFs, various functional domains were added to the TALE DNA-binding system to access the endogenous cellular DNA repair mechanisms. Nuclease activity is conferred via the fusion of the TALE domain to monomers of the FokI endonuclease to create a TALEN 3, 30 . A pair of TALEN arms is needed to target the cut site and bring together the FokI monomers 3, 30 . A targeted TALEN comprising
Key points
• Zinc-finger nucleases, transcription activator-like effector nucleases and CrISPr systems are powerful tools that are enabling new applications of genome engineering in diverse systems.
• Targeted double-stranded breaks in DnA activate diverse repair processes, such as non-homologous end joining, homology-directed repair and microhomologymediated end joining, which can be utilized to modify the nucleotide sequence of DNA.
• use of non-nuclease genomic tools enables the editing of single bases and locusspecific epigenetic targeting to modify gene expression.
• Applications of precision gene editing in nephrology include the generation of animal models to investigate kidney development and disease mechanisms as well as the development of targeted gene therapies.
• Genome editing in the kidney is challenging owing to anatomical barriers to gene delivery, limitations of vector size and immune responses against viral vectors, modified cells and editing proteins.
• Despite these challenges, precision gene editing has great potential to accelerate basic science in nephrology and to advance clinical practice through the development of novel therapies for renal diseases.
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. As a result of both this high base pair recognition count and the high innate specificity of each TALE repeat module, the commonly deployed TALEN systems exhibit high intrinsic binding accuracy with low off-target profiles [34] [35] [36] . An important difference between the TALEN and ZFN systems is that TALENs lack any known contextspecific assembly constraints 4, 37 . To date, no RVD combinations have been found to complicate either the binding ability or specificity of TALENs. The only common targeting constraint is the inclusion of a 5ʹ T recognition motif in front of each TALEN arm for enhanced binding affinity, but this sequence requirement has been eliminated using next-generation TALE scaffolds 38 . In addition, some reports suggest impaired binding of TALENs in regions of DNA that contain a methylated CpG island; however, this limitation has not substantially affected the usability of the TALEN platform 39, 40 . TALENs have proved to be far more easily assembled than ZFNs, with several published techniques for high-throughput assembly that use only a single tube for synthesis 30, [40] [41] [42] [43] [44] . In addition, TALEs have the fewest restrictions imposed on the design of the DNA-binding system and thus represent the most programmable DNA platform developed to date. The increased facility of use of TALENs compared with ZFNs is illustrated by the substantial increase in the number of gene editing publications in the wake of their development (FiG. 2) . However, the requirement for the synthesis of two custom proteins for each experimental TALEN setup represents a barrier to the use of TALEs in many laboratories, especially in those with limited experience in genome engineering.
CRISPR
Gene editing went mainstream when a naturally occurring ribonucleoprotein complex -CRISPR-Cas9 -was discovered to function as a new class of DNA recognition domain 45 . In CRISPR editing systems, a common protein such as Cas9 binds to a short guiding RNA that targets the resulting ribonucleoprotein to a specific region in the genome (FiG. 1c) .
Initially identified as an integral component of many bacterial immune systems, the first characterized CRISPR protein (Cas9) was shown to function [53] [54] [55] 57, 58 . Binding specificity is also dependent on the presence of a specific three-nucleotide sequence flanking the 3ʹ end of the protospacer known as the protospacer adjacent motif (PAM) 54, 59, 60 . This sequence is (N)GG (where N is any nucleotide) in the common CRISPR-Cas9 system from Streptococcus pyogenes and is determined by protein-DNA interactions 61 . This region is important for the endogenous function of CRISPR-Cas9 as it enables the system to avoid cutting the spacers stored in the genomic CRISPR DNA, which do not have the appropriate PAM sequence.
The CRISPR-Cas9 system was studied in relative obscurity for several years until it was shown to cut double-stranded DNA after DNA binding [62] [63] [64] [65] [66] [67] [68] . An important development that made the Cas9 system highly accessible was the fusion of crRNA and tracr-RNA into a single guide RNA (gRNA) 45 . As a result, the only requirement to create a custom DNA-interacting complex is to synthesize a single piece of single-stranded RNA to be co-delivered with Cas9. This simple twocomponent system with a single programmable element that can be readily generated by any modern molecular biology laboratory has substantially increased the accessibility of gene editing technology.
The targeting specificity of the commonly used CRISPR-Cas9 system does have some notable limitations [69] [70] [71] [72] . In particular, this system can exhibit off-target cutting 73 . The mechanism that underlies DNA or RNA matching with Cas9 and gRNAs often tolerates mismatches in the interaction, especially beyond the first 12 bases immediately adjacent to the PAM (known as the seed region), resulting in a measurable proclivity for nonspecific cutting 69, [74] [75] [76] . Whether this potential for offtarget activity is an important limitation in a particular gene editing application is highly project-dependent.
Many potential solutions to the problem of limited CRISPR-Cas9 specificity have been developed 35, 59, 72, 76, 77 . One approach mimics the TALEN and ZFN systems by fusing FokI monomers to a pair of catalytically inactive (dead) Cas9 proteins 78 . This catalytic inactivation makes Cas9 into a simple DNA recognition element 79 and increases the specificity of the CRISPR-Cas9 system by doubling the binding activity required to create a DSB owing to the requirement for dimerization of FokI 80 . A second approach is to use a pair of partially compromised Cas9 proteins designed to create a pair of trans-strand single-stranded DNA nicks in close proximity to one another 81 . This strategy might reduce the risk of potentially toxic off-target cutting 71 but can also reduce the efficiency of gene editing 81 . A third approach is to identify or engineer a more specific CRISPR system. Several modified Cas9 proteins with increased specificity compared with wild-type Cas9 have been developed with varying levels of success in maintaining catalytic efficiency 82, 83 . The ease of use and lowered cost of engineering using the CRISPR-Cas9 platform compared with TALENs and ZFNs has led to rapid expansion of gene editing into many laboratories in academia and industry. Genome editing technology is now accessible to the life-science community as a whole, and despite its limitations, the development of the CRISPR-Cas9 platform -the first easily accessible custom DNA endonuclease for gene editing -represents a major step in the democratization of gene editing.
CRISPR systems are common to many bacteria, and this rich family of related proteins is now being used to identify new DNA editing platforms such as Cas12a (formerly known as Cpf1) 84 . The Cas12a family has some features that are not common to the Cas9 family, including the ability to trim their own gRNAs and to induce a DSB that has base overhangs (FiG. 1d) . In contrast to the GG-rich PAM sequence in S. pyogenes Cas9, Cas12a proteins make use of a variety of AT-rich PAM sequences that make it easier to target Cas12a in certain areas of the genome 84 . Some Cas12a proteins also seem to have higher innate specificity than many Cas9 proteins 85 . The first RNA-binding platform using gRNAs (CRISPR-Cas13a) has now been generated 86, 87 , and other potential programmable RNA-binding systems have been characterized 88 . These systems, which are reminiscent of TALEs, consist of a modular series of protein motifs that each binds a single RNA base 88 . The ability to target RNA could lead to the establishment of an entirely new branch of genome engineering and enable novel areas of research. Potential applications of www.nature.com/nrneph this technology might include the development of RNA editing therapies with short-term effects that avoid the potential hazards associated with DNA editing, and the labelling and monitoring of mRNA molecules with temporal or tissue-specific expression.
Harnessing of DNA repair biochemistry Binding DNA is only the first step in gene editing.
Following the creation of a DNA lesion, various endogenous repair pathways function to create a chemical change in the genome (FiG. 3) . Gene editing thus revolves around the ability of cells to repair their DNA. The most prominent DNA repair pathway that is deployed in gene editing is DSB repair, which is the cellular response to DSBs induced by FokI, Cas9 or Cas12a. Four main categories of DSB repair are used in gene editing: NHEJ, homology-directed repair (HDR), SSTR and MMEJ. These mechanisms range in their efficiency and accuracy and thus possess dynamic mutagenic signatures. The use of different DNA endonuclease platforms can also affect the pathway utilized and the result of DSB repairs [89] [90] [91] [92] [93] [94] .
Genomic insults such as single-strand breaks have also been utilized to expand the gene editing toolkit 95, 96 . For example, activation of the mismatch repair pathway can be used to directly edit single nucleotides without the creation of DNA DSBs.
Non-homologous end joining
NHEJ is a prolific response to DSBs that functions to maintain genomic integrity 95 . In this process, genomic repair enzymes identify the DSB and either one or both DNA strands are resected or filled in as necessary, usually creating blunt ends. New bases can also be polymerized and incorporated into the DNA sequence, and the ends are ligated to restore continuity to the DNA molecule. The lack of template and the somewhat random resection and polymerization of the DNA ends results in the creation of insertions or deletions of various lengths known as indels (FiG. 3a) , which can produce variable mutational signatures. NHEJ is commonly used to create frameshift mutations in the coding region of DNA in order to knock out a protein. Alternatively, two distant cis-DSBs can be generated to delete the double-stranded DNA sequences that are homologous to the sequence that is adjacent to the DSB. d | Oligo-directed HDR can introduce small changes through the introduction of a short single-stranded (SS) DNA template flanked with DNA sequences that are homologous to the regions on either side of the DSB. e | Microhomology-mediated end joining (MMEJ) can be used to create small reproducible deletions. This repair pathway functions by annealing small homologous regions on each side of the DSB. Unbound DNA flaps are removed and the ends are ligated, resulting in the removal of one homology arm and the intervening region. f | MMEJ can also be used to insert exogenous DNA through the introduction of a template with matching microhomology arms. g | Base editors can be used to generate single-nucleotide polymorphisms without introducing a DSB. By targeting a cytosine deaminase to a specific target in the genome, a cytosine can be converted to a uracil, resulting in a mismatched base. This mismatch is then recognized and repaired, generating a single base change depending on which strand is used as the repair template. The repair template can be selected by repeated nicking of the strand to be modified. WT, wild type. Adapted from REF.
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nATure revIewS | NEPhRoloGy sequence between them, enabling NHEJ to delete whole genes (FiG. 3b) . NHEJ is active across multiple species, enabling most model systems to be edited. Moreover, as no known context restrictions to NHEJ exist, edits can be made anywhere in the genome. Although NHEJ is most likely to introduce short indels or large deletions, the process can also be used to create large insertions by introducing a blunt-ended DNA template 97 . However, these insertions are subject to the same randomness of repair as other DNA edits made using NHEJ, and the ends of the insertion will normally contain indels.
Homology-directed repair
Several distinct yet interconnected mechanisms of repair that rely on the use of a DNA template homologous to the sequence flanking the DSB operate in tandem with NHEJ, although normally with less frequency 95, 98 . Collectively, these pathways are referred to as HDR, with the best characterized being HR. Following a DSB, HR proteins use a template molecule of double-stranded DNA to correct the damaged DNA 99 . The donor double-stranded DNA molecule contains long stretches of DNA sequences (>500 bp) that are homologous to either side of the break and are used as a template for repair. The result is a newly synthesized stretch of genomic DNA that is identical to the donor molecule (FiG. 3c) .
HR has been utilized to introduce exogenous DNA into chromosomes 100 . This process is accomplished by designing a donor molecule with long homology arms that flank the integration cargo. By co-delivering this exogenous template with a custom nuclease, the desired cargo can be incorporated into the genomic DNA. Unlike NHEJ, HR is usually fairly inefficient and often requires antibiotic selection or an equivalent enrichment step to identify chromosomes that contain the newly synthesized sequence, limiting its application.
Single-strand template repair
To increase the efficiency of gene editing, a variety of homologous donor molecules have been utilized as templates for DNA repair. The simplest of these templates are single-stranded oligodeoxynucleotides (ssODNs) with very short homology arms (<100 bp) that can be incorporated into DNA at the site of a DSB via the SSTR pathway in which a single-stranded DNA donor molecule is either incorporated into the genome or used as a template for DNA repair (FiG. 3d) . The precise mechanism of repair used to integrate a ssODN sequence remains unclear, and this process can result in either an HDR signature (precise integration of the template) or an NHEJ signature (indel formation) depending on the model system used [101] [102] [103] [104] [105] . Although oligo-mediated HDR can often lead to higher rates of integration than are achieved with traditional HR, this approach is typically deployed to integrate sequences of 50 bp or fewer owing to limitations of the repair pathway and of single-stranded DNA synthesis 106 . The wide-ranging mechanisms of HDR combined with the faithful accuracy of template-dependent repair enables the creation of almost any desired DNA change.
Unfortunately, the lower relative frequency of this event than that achieved with NHEJ often requires exhaustive trials and screens to find the line or cell with the intended change. Current research is investigating what makes a good candidate site for HDR 98, 99 . If such a site is identified, the use of oligo-mediated HDR for gene editing will likely increase.
Microhomology-mediated end joining
Another mechanism of DNA repair that is emerging as an approach to gene editing is MMEJ (also known as alt-NHEJ or alt-EJ), which shares characteristics with both NHEJ and HDR. MMEJ repairs a DSB by annealing small homologous regions on each side of the break, generating a predictable small deletion in between. The precise contextual and cellular conditions that bias a DSB to be repaired via MMEJ rather than classic NHEJ are not fully understood 107, 108 . During MMEJ, the 5ʹ strands of both ends of the DSB are resected, leaving overhanging 3ʹ tails on each molecule 109 . These overhangs are aligned through short regions of homology, leaving unmatched 'flaps' of DNA at each side of the paired homologous region. The remaining single-stranded DNA regions are used as templates for DNA synthesis, whereas the flaps are cleaved off, enabling the nick between the newly synthesized DNA and the homologous region to be ligated, resulting in restoration of continuity within the DNA molecule 110 . Resection of the DNA flaps created by homologous matching results in the removal of a short stretch of nucleotides central to the original DSB together with one of the original homology arms. This intrinsic deletion pattern, which is unique to regions predisposed to engage in MMEJ activity, makes the creation of specific indels a predictable and reproducible event (FiG. 3e) .
The improved predictability of the MMEJ repair pathway compared with NHEJ and HDR makes it uniquely useful for the precise integration of exogenous DNA 91, 94, 111 . The introduction of a double-strand template DNA flanked with short microhomology arms (<100 bp) has been shown to result in precise integrations 112 (FiG. 3f) . This integration has the potential to be as accurate as repair with classical HR and, in some cases, as efficient as NHEJ 113 . However, the factors that have a role in efficient integration are not currently understood. For example, how the balance of NHEJ and MMEJ affects the proclivity to integrate a donor molecule using this method is unclear. Although the mechanism by which MMEJ proceeds is not yet fully understood, attempts at characterization have demonstrated that some re pair enzymes show preferential activity in different repair pathways 104, 114 . As MMEJ becomes better characterized and more predictable, this pathway may prove incredibly useful for its propensity to produce a small subset of predictable mutations as efficiently as NHEJ and might also be utilized for precise integrations of DNA ranging from point mutations to several kilobases. This combination of efficiency and accuracy makes MMEJ an especially potent mechanism that may unlock entirely new options for gene editing.
www.nature.com/nrneph
Mismatch repair
Rather than creating a DSB, an emerging method of precision gene editing modifies a single DNA base by activating a series of mismatch repair mechanisms that are capable of creating single-nucleotide substitutions. These base editor systems function via the fusion of a nucleotide-modifying enzyme such as a deaminase to an existing DNA recognition system such as a catalytically inactivated Cas9 protein 115 . Upon binding to the target, the functional enzyme modifies a single DNA base (for example, by deaminating a cytosine to a uracil). Nicking of the complementary DNA strand forces strand excision during repair, resulting in the use of uracil as a template and the net insertion of an adenine. During DNA replication, uracil is read as thymine, resulting in a C-to-T transition (FiG. 3g) . A uracil-DNA glycosylase inhibitor is often used to prevent the removal of uracil before and during replication 96 . A novel adenine base editor that is capable of deaminating adenine has also now been generated through enhanced molecular evolution 116 . Base editing is a promising strategy for gene therapy because many genetic disorders are caused by missense polymorphisms and this approach offers a path to repair that does not cause further damage to DNA via the introduction of DSBs 115, [117] [118] [119] [120] [121] [122] [123] [124] . Although the efficiency and specificity of base editing is still being improved, this strategy has the potential to deliver targeted single substitutions much more efficiently than approaches that rely on integration of exogenous DNA via homology-dependent repair mechanisms.
Locus-specific epigenetic targeting
In addition to using the available DNA-binding platforms to modify the nucleotide sequence of DNA, they can be used to modulate how the cell interprets DNA, either by direct chemical modification of the DNA or histones or through the creation of artificial transcription factors that modify gene expression (FiG. 4) . These methods have many potential advantages as they do not require the formation of a DNA lesion such as a DSB or a mismatched base, and the resulting epigenetic modifications are usually reversible. Three primary methods are used to modulate DNA and gene expression: methylation, acetylation and programmable transcription factors. Each of these methods can be accomplished by the fusion of the appropriate functional domain to any of the DNA-binding systems discussed above.
DNA methylation
DNA methylation and demethylation are key mechanisms that physically mark DNA and enable epigenetic control of cellular processes 125 . For example, by fusing DNA-binding domains to a sequence-nonspecific methyltransferase, a methyl group can be added to a CpG site 126 (FiG. 4a) . Promoter and enhancer regions with high methylation of these sites modulate transcription of the associated genes 127 . This effect can be reversed by utilizing programmable DNA-binding platforms fused to demethylase domains such as the ten-eleven translocation (TET) enzymes that oxidize methylated cytosines 128 . Both of these approaches have been applied using ZFs, TALEs and CRISPR systems to activate and deactivate locus-specific regions within the genome 125, [129] [130] [131] [132] .
Histone acetylation
Acetylation and deacetylation of histones is a common chemical method of modifying gene expression 125 ( FiG. 4b) . Histone acetyltransferases (HATs) and histone deacetylases (HDACs) target lysine residues on the tail chains of histone proteins, leading to altered charge of the lysine 133, 134 . In the case of acetylation, the positive charge of the lysine is neutralized, reducing the ability of the histone to bind the negatively charged backbone of DNA 125 . Therefore, acetylation acts indirectly on DNA expression both by modulating protein-protein interactions and by increasing the accessibility of the targeted regions, which increases the steric favourability of promoter and enhancer binding 135 . HDAC fused to catalytically dead Cas9 or other programmable DNAbinding platforms has been shown to have the opposite effect, decreasing the steric favourability of promoter and enhancer binding in some, but not all, cell lines 136 . These inconsistent outcomes are likely the result of nonspecific deacetylase activity. Determining the specificity of acetylation and deacetylation-targeted epigenetic technology is an active area of research.
Artificial transcription factors
The concept of using programmable DNA-binding platforms as guided transcription factors relates to the natural origins of ZF domains in the transcription factors of eukaryotes and archaea [137] [138] [139] and of TALEs in proteins that are secreted by pathogenic plant bacteria and modulate gene expression within the host cells 140 . Both of these systems can be easily modified to activate or repress genes by the fusion of different transcriptionregulating domains (FiG. 4c) . CRISPR systems that have been catalytically inactivated can also be used to create artificial transcription factors 141 . Krüppel-associated box (KRAB) domains are found in approximately 30% of endogenous ZF-related proteins and are commonly used as repression domains in artificial transcription factors 137, 142 . The most commonly used activator domain is that of the herpesvirus tegument protein VP16 (REF. 143 ). This domain can be used alone but is more often repeated four times to create a VP64 activation domain 144 . Activation or repression domains can be utilized for epigenome editing by targeting them to the promoter or enhancer region of the target gene.
Applications in nephrology
Since the late 1990s, studies using nontargeted gene delivery have shown the potential of genetic engineering in nephrology (TABlE 1) . Building on this foundation, precision gene editing has been used in renal research to achieve both gene inactivation and gene editing in a variety of model systems from single cells to whole animals. These studies have provided new insights into kidney development and mechanisms of disease and have illustrated the potential of genome editing as a tool to enable progress in xenotransplantation and targeted gene therapy.
Generation of animal models
Tools such as ZFN, TALEN and CRISPR-Cas9 enable the editing of endogenous genes in a variety of cellular and in vivo model systems (TABlE 2) . Many studies have applied these technologies to the kidney using renal cell culture 145 and kidney organoids 146 . The ability to generate vertebrate models using gene editing is especially valuable, and kidney diseases are now being modelled using precision gene editing tools in a variety of organisms including zebrafish 147 , tilapia 148 , Xenopus 149 , mouse [150] [151] [152] [153] , rat [154] [155] [156] and pig 157 . As rat and pig models might more faithfully represent human disease than do mouse models, the advent of precision gene editing in these animals is particularly exciting 157 . The costs of raising and maintaining lines of pigs to achieve genetic homogeneity are much higher than that of mice, but these expenses must be weighed against the much higher costs of a failed clinical trial in terms of both money and human life.
Gene inactivation.
To date, the majority of studies that have used precision gene editing tools to generate animal models have used NHEJ to knock out genes by inducing truncating mutations. Such models have been used to characterize the roles of genes and proteins in a variety of diseases, including glomerulonephritis, hypertension, polycystic kidney disease (PKD), renal agenesis and renal fibrosis 147, [151] [152] [153] [154] [155] 158, 159 . For example, mouse studies in which Pde1a was mutated using TALEN demonstrated a role of this gene in the pathogenesis of PKD 152, 153 , and CRISPR-Cas9 technology has been used to validate the identification of a novel renal agenesis gene, GREB1L 151, 158, 159 . Targeted gene editing. TALENs and CRISPRs can also be employed to make targeted gene edits in cells and model organisms. This technology enables the recapitulation of disease-causing sequence variations using targeted integration approaches (FiG. 3) . For example, CRISPR-Cas9 with HR has been used to re-create the p.C147 W mutation found in patients with uromodulinassociated kidney disease in mice 160 . This new mouse model more faithfully reproduced the human phenotype (including progressive kidney disease leading to renal failure) than did previous models and provided insight into the pathogenic mechanisms of the mutation (that is, the involvement of endoplasmic reticulum stress, apoptotic signalling and decreased autophagy). Moreover, in this model, tumour necrosis factor (TNF) blockade resulted in a reduction in caspase 3 activation and tubule cell death, suggesting a potential therapeutic benefit.
A few studies have successfully combined CRISPR with HR to tag edited genes in Xenopus and renal cell cultures 145, 149 . These tagged genes enable the cellular and subcellular expression and trafficking of the encoded endogenous (albeit modified) proteins to be defined. This approach is potentially more useful than standard techniques for investigating gene expression such as in situ hybridization and antibody labelling, which are limited by the availability and specificity of reagents as well as by the inability to distinguish low and/or ubiquitous expression of the labelled genes from non-specific background staining.
Xenotransplantation
Another application in which gene inactivation by programmable DNA nucleases is potentially valuable is in the generation of organs suitable for xenotransplantation. Pigs are a promising source of such organs provided that several obstacles, including the transmission of porcine endogenous retroviruses (PERVs) to the transplant recipients, can be overcome. CRISPR-Cas9 inactivation of PERVs in a porcine cell line prevented transmission to human cells in vitro 161 . In addition, PERV-inactivated pigs have been generated using somatic cell nuclear transfer 162 . Although several challenges such as immunological issues remain, these studies illustrate the essential contributions of gene editing to the development of xenotransplantation 163 .
Targeted gene therapies
New technologies for precision genome editing in somatic cells are potentially valuable as therapeutics. For example, studies using CRISPR-Cas9 have demonstrated proof of principle of this technology as a therapeutic approach in a mouse model of Duchenne muscular dystrophy (DMD) [164] [165] [166] . In these studies, CRISPR-Cas9 (delivered either locally or systemically using an adeno-associated virus (AAV)) was used to induce exon skipping to avoid a truncating mutation and partially restore dystrophin expression. This approach built on a strategy used in a previous clinical trial of morpholino oligomers 167 . In the field of nephrology, gene editing could potentially be used to correct base pair variants in monogenic diseases, such as steroid-resistant nephrotic syndrome,
Morpholino oligomers
Synthetic modified oligomers that are capable of sterically inhibiting translation of specific RNAs in a targetable manner.
www.nature.com/nrneph
PKD, urinary stone disease and congenital anomalies of the kidneys and urinary tract in which these types of mutation are common and a small amount of functional protein might be protective 168 . In diseases in which gene dosage seems to be important and a normal allele is present, such as autosomal dominant PKD, upregulation of the normal copy of the gene may be beneficial.
Remaining challenges
Despite the promise, multiple issues remain to be addressed to enable precise and efficient performance of genome editing in the kidney. These issues include the effects of pharmacology, vector tropism and immune responses against vectors and newly expressed proteins including repaired proteins and genome editing AGT, angiotensinogen; AP-1, activator protein 1; CTGF, connective tissue growth factor ; EGR1, early growth response protein 1; ERK2, extracellular-signal-regulated kinase 2 (also known as MAPK1); FGS, focal glomerulosclerosis; HGF, hepatocyte growth factor ; HVJ, hemagglutinating virus of Japan; IgA , immunoglobulin A ; IM, intramuscular ; IP, intraperitoneal; IV, intravenous; MSC, mesenchymal stem cell; NA , not applicable; ND, no data; PAI1, plasminogen activator inhibitor 1; p-AKT, phospho-AKT (RACα serine/threonine-protein kinase); p-eNOS, phospho-endothelial nitric oxide synthase; siRNA , small interfering RNA ; SMAD, mothers against decapentaplegic homologue; STZ, streptozotocin; TGFβ1, transforming growth factor-β1; UUO, unilateral ureteral obstruction; VEGF, vascular endothelial growth factor. nATure revIewS | NEPhRoloGy proteins. In the setting of renal disease, these issues are particularly challenging because the location and anatomy of the kidney make delivery of vectors very difficult. Remaining questions about the precision of gene editing and off-target effects also need to be addressed before widespread human treatment is feasible.
Gene delivery to the kidney
As the first organ destinations of most injected particles are the liver and spleen, few vector particles reach the kidneys. In addition, the diameter of the afferent arteriole that feeds the glomerulus is a simple and effective barrier to kidney vector delivery. The arteriole is approximately 10 nm in diameter, whereas most viral and non-viral gene delivery vectors are 20-200 nm in diameter. If a vector manages to squeeze through the arteriole, it then confronts the stringent molecular mass cut-off of the glomerulus. Only proteins below 50 kDa in size are thought to readily pass through this barrier, whereas most gene therapy vectors are megadaltons in size. AAV vectors are by far the most popular vectors used for in vivo gene therapy and are only 25 nm in diameter 169 . Although these small viral vectors can extravasate into tissues after intravenous injection and mediate impressive transduction of multiple tissues in mice 170, 171 , most do not efficiently transduce kidney cells 172 . Rare CD31-positive endothelial cells and epithelial cell adhesion molecule (EpCAM)-positive proximal tubules can be transduced using intravenous delivery of AAV1, AAV8 and AAV9 vectors, but podocytes are not modified using this approach 172 . Saturation of kidney cells after intravenous injection of AAV vectors is not observed.
Although the standard intravenous route of vector delivery is not efficacious for kidney gene therapy, alternative approaches are being developed. For example, retrograde injection of non-viral, AAV or adenovirus vectors into the ureter or directly into the kidney capsule can bypass some of the barriers to delivery 173 .
Limitations of vector size
The small size of AAV in part explains its popularity as a vector for gene therapy. However, this small size is also a limitation for gene delivery because AAV can only package 4.5 kb of sequence. This capacity is appropriate for delivering a small gene for renal gene therapy but is not suitable for the delivery of medium to large genes. For example, AAV can easily carry the ~3,000 bp cDNA for PKD2, but three AAV vectors would be required to carry the ~13,000 bp PKD1 cDNA.
As two ZFNs separated by a 2A peptide and furin cleavage sequence with a DNA repair substrate of 750 nucleotides can fit into AAV 174 , this vector can potentially be used to deliver ZFN to the kidney for renal genome editing in vivo. By contrast, a single TALEN expression cassette can easily exceed 3.5 kb, making it impossible to package the two TALENs needed to induce DNA DSBs plus a repair template into a single AAV vector 175 . For CRISPR gene editing, one or two AAVs would be required to carry the Cas9 and gRNA sequences, and an additional AAV would likely be needed to carry the repair template, which would be restricted to less than 4.5 kb in size. Given the difficulties in transforming many cells with a single vector in vivo, gene delivery approaches requiring more than one vector are unlikely to be feasible unless co-delivery approaches are optimized.
In contrast to AAV, adenovirus vectors can carry up to 36,000 bp of transgene sequences 176 . Most adenovirus vectors described in the literature are first-generation adenoviruses that can carry ~7 kbp of sequence as they retain most adenovirus genes and open reading frames. However, these vectors provoke strong immune responses owing to leaky expression of adenovirus proteins in transduced cells 177 . Moreover, a third-generation adenovirus vector caused systemic inflammatory 
Immune responses against edited cells
As a key role of the immune system is to protect against viral and bacterial infections, it is unsurprising that gene delivery by viral vectors and the expression of bacterial proteins can provoke immune responses against edited cells. These responses limit the long-term efficacy of viral vectors for gene therapy.
A surprising advantage of the use of AAV vectors in small animals is that they were found to be less immunogenic and to provoke lower anti-viral and antitransgene-product immune responses than did adenovirus vectors 179 . Early studies suggested that AAV vectors also have reduced immunogenicity compared with adenovirus vectors in humans 180 . However, the delivery of large doses of AAV into humans provokes strong T cell responses against the AAV capsid proteins that can destroy any modified cell that was generated during gene therapy 181 . This problem can be circumvented to a certain degree by the use of lower doses of rarer AAV serotypes and by applying transient immunosuppression during vector delivery.
Helper-dependent (HD)-adenovirus vectors have been designed to address concerns regarding the immunogenicity of adenovirus vectors and are appropriate to use for in vivo delivery, particularly if they are confined to the kidney. As all viral genes and open reading frames are deleted in HD-adenovirus vectors, no adenovirus proteins are produced in the transduced cells. Therefore, these vectors generate lower adenovirus T cell responses against transduced cells than do first-generation or second-generation adenovirus vectors 182, 183 . This reduced immunogenicity enables transgene expression over years 184, 185 . For example, in an ongoing study, baboons that were treated once with HDadenovirus vectors were still expressing the transgene protein more than 7 years later 176 . This finding suggests that HD-adenoviruses are promising vectors for gene therapy in the kidney, provided that these large vectors are able to reach the target cells.
In addition to the viral vectors, many of the proteins used in precision gene editing are foreign to the human immune system and may stimulate immune responses against the modified cells. For example, healthy people have antibodies and antigen-specific T cells against Cas9 proteins from S. pyogenes (spCas9) and Staphylococcus aureus (saCas9) 186 . Transient expression of foreign editor proteins may help to evade immune responses against edited cells. In addition, the use of immunosuppression during AAV gene therapy might help to reduce the detection of transiently expressed foreign proteins by the immune system 181 .
Conclusions
The field of precision gene editing has advanced rapidly over the past 7 years with the development of several new and accessible technologies for editing the genome. These ground-breaking tools have expanded the utility of multiple model organisms and tissues not only for gene inactivation but also for the induction of specific mutations found in patients. They have thereby enabled improved understanding of renal disease and advances in the development of therapeutic approaches such as xenotransplantation and gene therapy. Continued research into gene editing technologies is required to overcome the remaining barriers to gene editing in the kidney, particularly regarding the specific and efficient targeting of this organ. Despite the remaining challenges and risks that are associated with the therapeutic use of gene editing, several ongoing trials are testing CRISPRs, TALENs and ZFNs for the treatment of various diseases including renal cell carcinoma 187 and other cancers, beta thalassaemia 188 , haemophilia 189 , HIV 190 and mucopolysaccharidosis 191 . These trials are a testament to the accessibility, variety and efficiency of precision genome editing approaches as well as to the value of basic research and its potential transformative role in advancing clinical practice. 
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